Identification of a novel variant CYP2C9 allele in Chinese

Dayong Si, Yingjie Guo, Yifan Zhang, Lei Yang, Hui Zhou, Dafang Zhong
  • Pharmacogenetics, July 2004, Wolters Kluwer Health
  • DOI: 10.1097/01.fpc.0000114749.08559.e4

First identification of novel variant CYP2C9*13 in Chinese

What is it about?

SNPs in the CYP2C9 gene are determinants of the metabolic phenotype. The present study focused on a Chinese poor metabolizer of both lornoxicam and tolbutamide. By sequencing his CYP2C9 gene, we identified the poor metabolizer heterozygous for the CYP2C9*13 together with the CYP2C9*3.

Why is it important?

This novel CYP2C9*13 allele was correlated with reduced plasma clearance of drugs that are substrates for CYP2C9. Frequency analysis in 147 Chinese males indicated approximately 2% of the Chinese population carry the allele. Biopharm.

Perspectives

Dayong Si (Author)
Jilin University

More frequency analysis of CYP2C9*13 in Asian populations and the identification of a long-range haplotype containing the CYP2C9*13 and CYP2C19*2 and CYP2C9*1B haplotype group can be found in another paper: Drug Dispos. 33: 342–345 (2012) The CYP2C9*13 allele is associated with decreased enzymatic activity both in vitro and in vivo.( in another paper: DMD 33:749–753, 2005)

Read Publication

http://dx.doi.org/10.1097/01.fpc.0000114749.08559.e4

The following have contributed to this page: Dayong Si